CCR5 determinants for the HIV transmitted founder phenotype
HIV 传播创始人表型的 CCR5 决定因素
基本信息
- 批准号:10760884
- 负责人:
- 金额:$ 23.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAIDS preventionAddressAffinityAmino Acid SequenceAnti-Retroviral AgentsBindingCCR5 geneCD4 Positive T LymphocytesCell surfaceCellsCharacteristicsComparative StudyDataData SetDevelopmentDimerizationDown-RegulationDrug TargetingEarly DiagnosisEnvironmentExposure toFluorescence Resonance Energy TransferGTP-Binding ProteinsGenotypeGoalsHIVHIV Envelope Protein gp120HIV InfectionsHIV vaccineHumanIn SituIn VitroIndividualInfectionInterventionKnowledgeLigandsLinkLymphocyteMacrophageMeasuresMediatingMembraneMethodsMolecularMonoclonal AntibodiesNatureOpen Reading FramesPhenotypePopulationPreventionProductivityProteinsReagentReceptor SignalingRecyclingReportingResistanceResolutionRoleSIVSignal TransductionSortingStructureSulfateSurfaceTestingTranslatingVaccine DesignViral GenesViral ProteinsVirusVirus DiseasesVirus Replicationantagonistcell typechemokinechronic infectiondetection sensitivityenv Gene Productsexperimental studyhumanized mouseimaging approachimaging modalityimmunoreactivityin vivoinnovationmonocytemutantnef Proteinoptical imagingpressurepreventreceptorsimian human immunodeficiency virussuperresolution imagingtransmission processultra high resolutionvirus envelope
项目摘要
ABSTRACT
HIV is naturally transmitted as a virus swarm, which establishes infection via only one or few transmitted/founder
(T/F) viruses. Several observations strongly indicate that T/F viruses are non-randomly favored for productive
transmission via shared signature genotypic and phenotypic characteristics. Current knowledge regarding Env-
coreceptor interactions suggest innovative concepts to explain the T/F phenotype. T/F virus envelopes of all
subtypes preferentially use the CCR5 coreceptor for entry in vitro and in vivo. Yet cell surface CCR5 is expressed
in multiple functional and antigenic forms with differential sensitivity to the antiretroviral CCR5 antagonist
maraviroc (MVC); affinity for natural chemokine ligands, and/or reactivity with anti-CCR5 monoclonal antibodies
(mAbs). Further, the abilities of various anti-CCR5 mAbs to inhibit CCR5 interactions with either tagged soluble
gp120s or pseudoviruses vary according to virus strain and target cell-type. Collectively, these findings prompt
the central hypothesis for this exploratory project: as a class, T/F viruses utilize signature CCR5 subpopulation(s)
that potentially favor more efficient entry and virus replication. Tests of this hypothesis will exploit how active
infection downregulates a “footprint” in the surface CCR5 population, distinguishing which subsets have been
engaged by HIV. We recently reported how innovative superresolution optical imaging methods reflect CI virus
use of distinct antigenic CCR5 forms. The two specific aims of this project will employ similar approaches to
generate an unprecedented view of T/F coreceptor usage and entry on primary cells (human monocytes,
lymphocytes and CD4+ T cells). The definition of “T/F CCR5” usage will impact HIV prevention/treatment efforts
by informing the development of more potent and selective CCR5-based interventions and by elucidating
complementary aspects of Env structure/function that confer coreceptor selectivity and the T/F phenotype. Such
features can be explored by molecular methods and translated to HIV vaccine design.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anthony L DeVico其他文献
Anthony L DeVico的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anthony L DeVico', 18)}}的其他基金
Detection Assays for Virion Susceptibility to HIV Broadly Neutralizing Antibodies in Plasma and Culture Fluids
血浆和培养液中病毒体对 HIV 广泛中和抗体敏感性的检测分析
- 批准号:
10675310 - 财政年份:2023
- 资助金额:
$ 23.18万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10653146 - 财政年份:2021
- 资助金额:
$ 23.18万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10445321 - 财政年份:2021
- 资助金额:
$ 23.18万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10324861 - 财政年份:2021
- 资助金额:
$ 23.18万 - 项目类别:
Project 1-Mechanism of Anti-Gp120 Antibody Persistence
项目1-抗Gp120抗体持久性机制
- 批准号:
9141192 - 财政年份:2016
- 资助金额:
$ 23.18万 - 项目类别:
Single Chain Complex Vaccines and Protective Immunity
单链复合疫苗和保护性免疫
- 批准号:
7515045 - 财政年份:2005
- 资助金额:
$ 23.18万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7121362 - 财政年份:2005
- 资助金额:
$ 23.18万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7039242 - 财政年份:2005
- 资助金额:
$ 23.18万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7510135 - 财政年份:2005
- 资助金额:
$ 23.18万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7334749 - 财政年份:2005
- 资助金额:
$ 23.18万 - 项目类别:
相似海外基金
HIV/AIDS prevention and intervention: HIV surveillance methods, Per-exposure prophylaxis eligibility and HIV/STI testing behaviours among a cohort of people living with HIV.
HIV/艾滋病预防和干预:HIV 感染者群体中的 HIV 监测方法、每次暴露预防资格和 HIV/STI 检测行为。
- 批准号:
495195 - 财政年份:2023
- 资助金额:
$ 23.18万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10013921 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10181081 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
UCLA AIDS Prevention and Treatment Clinical Trials Unit
加州大学洛杉矶分校艾滋病预防和治疗临床试验单位
- 批准号:
10166309 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10597008 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10386931 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9921510 - 财政年份:2019
- 资助金额:
$ 23.18万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9753631 - 财政年份:2019
- 资助金额:
$ 23.18万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
10265667 - 财政年份:2019
- 资助金额:
$ 23.18万 - 项目类别:
Closing the Gap: Involving Indigenous Elders and youth in HIV/AIDS prevention using participatory filmmaking
缩小差距:利用参与式电影制作让土著老年人和青年参与艾滋病毒/艾滋病预防工作
- 批准号:
364681 - 财政年份:2017
- 资助金额:
$ 23.18万 - 项目类别:














{{item.name}}会员




